Composition for treating gallinaceous vibrio hepatitis and preparation method thereof

A chicken Vibrio hepatitis and composition technology, which is applied in drug combinations, medical preparations containing active ingredients, antibacterial drugs, etc., can solve the problems of inability to kill pathogens, serious bacterial drug resistance, and no therapeutic effect of hepatitis, etc. problem, achieve the effect of reducing the chance of drug resistance, speeding up recovery, and preventing secondary infection

Inactive Publication Date: 2010-02-17
天津市普天惠生物科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Chicken vibrio hepatitis is also called chicken Campylobacter hepatitis. The pathogen is Campylobacter jejuni. The disease course is slow and the incidence is high. It can reduce egg production by 25-35%. Young chickens may delay egg production or low egg production. , the most obvious case change is hepatitis or hepatic necrosis. Although the mortality rate of this disease is low, it is easy to cause the body's resistance to decline, and it is easy to cause secondary infections such as E. coli and Salmonella, resulting in death.
[0003] Now the disease is more difficult to treat, and common medicines are used. While killing the pathogen, they often have no therapeutic effect on hepatitis. Similarly, they cannot kill the pathogen while treating hepatitis. In addition, the drug resistance of bacteria is more serious now. Antibacterial drugs can not control the disease very well, and the current breeders cannot reasonably cooperate or combine drugs, resulting in poor treatment effect and serious losses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Weigh 5kg of sulfamethoxine sodium, 15kg of acemethaquine, 1kg of trimethoprim lactate, 1kg of glucuronolactone, 10kg of taurine, and 68kg of anhydrous glucose after sieving, and mix them thoroughly for 1 hour. , to obtain the composition of the present invention for the treatment of vibrio hepatitis in chickens.

Embodiment 2

[0018] Take by weighing 20 kg of sulfamethoxine sodium after sieving, 2 kg of acemetaquine, 4 kg of trimethoprim lactate, 10 kg of glucuronolactone, 2 kg of taurine, and 62 kg of anhydrous glucose and fully mix for 1 hour. After mixing, That is, the composition for treating vibrio hepatitis of the present invention is obtained.

Embodiment 3

[0020] Weigh and sieve 8kg of sulfamethoxine sodium, 12kg of methaquine, 1.6kg of trimethoprim lactate, 2kg of glucuronolactone, 7kg of taurine, and 69.4kg of anhydrous glucose, mix thoroughly for 1 hour, and mix well After that, the composition for treating vibrio hepatitis of the present invention is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a composition for treating gallinaceous vibrio hepatitis and a preparation method thereof, which aims at providing a composition capable of treating gallinaceous vibrio hepatitis infection, reducing germ medicine resisting probability, treating both principal and secondary aspects of diseases and preventing other bacterial secondary infection; and the invention also discloses a preparation method of the composition. The composition for treating gallinaceous vibrio hepatitis comprises the following components by weight percent: 5-20 percent of sulfamonomethoxine sodium,2-15 percent of mequindox, 1-4 percent of trimethoprim lactate, 1-10 percent of glucurolactone, 2-10 percent of taurine and the balance of anhydrous dextrose. The composition for treating gallinaceousvibrio hepatitis combines the sulfamonomethoxine sodium and the mequindox, effectively kills gallinaceous vibrio hepatitis pathogeny, i.e. an empty intestine campylobacter, reduces medicine resistingprobability and has a stronger inhabiting or killing function. The trimethoprim lactate enhances an antibacterial action of the sulfamonomethoxine sodium and has better treatment effect; the glucurolactone can detoxify, increase glycogen and reduce fat storage; and the taurine has the functions of inflammation resistance, refrigeration and liver and gall enhancement.

Description

technical field [0001] The invention relates to a composition for treating vibrio hepatitis in chickens and a preparation method thereof. Background technique [0002] Chicken vibrio hepatitis is also called chicken Campylobacter hepatitis. The pathogen is Campylobacter jejuni. The disease course is slow and the incidence is high. It can reduce egg production by 25-35%. Young chickens may delay egg production or low egg production. , the most obvious case change is hepatitis or hepatic necrosis. Although the mortality rate of this disease is low, it is easy to cause the body's resistance to decline, and it is easy to cause secondary infections such as E. coli and Salmonella, and cause death. [0003] Now the disease is more difficult to treat, and common drugs are used. While killing the pathogen, they often have no therapeutic effect on hepatitis. Similarly, they cannot kill the pathogen while treating hepatitis. Advanced antibacterial drugs cannot control the disease well...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7012A61K31/635A61K31/498A61K31/505A61K31/185A61P1/16A61P31/04
CPCY02A50/30
Inventor 徐克福
Owner 天津市普天惠生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products